Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 63 results for chronic fatigue syndrome

  1. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)

    This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.

  2. Postural hypotension in adults: fludrocortisone (ESUOM20)

    Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

  3. Physical activity: exercise referral schemes (PH54)

    This guideline covers exercise referral schemes for people aged 19 and older, in particular, those who are inactive or sedentary. The aim is to encourage people to be physically active.

  4. Diagnostic tests: What diagnostic tests are clinically and cost effective in people with suspected myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)?

    people with suspected myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)? Any explanatory notes(if...

  5. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  6. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  7. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)

    This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.

  8. Coeliac disease: recognition, assessment and management (NG20)

    This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

  9. Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)

    This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.

  10. Dietary strategies: What is the clinical and cost effectiveness of dietary strategies in managing ME/CFS?

    from guidance Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management Number NG206 Date issued

  11. Self-monitoring management strategies: What is the clinical and cost effectiveness of self-monitoring strategies and techniques in guiding energy management?

    from guidance Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management Number NG206 Date issued

  12. Sleep management strategies: What is the clinical and cost effectiveness of sleep management strategies in managing ME/CFS?

    from guidance Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management Number NG206 Date issued

  13. Diagnostic criteria: In people with suspected ME/CFS, how effective is the NICE 2021 consensus-based diagnostic criteria in identifying people with ME/CFS?

    from guidance Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management Number NG206 Date issued

  14. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  15. A core outcome set: What core set of relevant health outcome measures should be used for trials of treatments for ME/CFS and managing symptoms of ME/CFS?

    from guidance Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management Number NG206 Date issued